VDRM FULL DD PACKAGEALL THE DD ON VDRM YOU NEED RIGHT HERE (repost)
2dollarbill Saturday, 08/19/17 10:19:12 AM
Re: None
Post #
26410
of 26411 Go
ALL THE DD ON VDRM YOU NEED RIGHT HERE
FDA approved products that ViaDerma (VDRM) offers:
-skin cancer therapies (Cantrile)
-stem cell therapy product (TetraStem Plus)
-topical antibiotics (TetraStem the world’s strongest broad-spectrum topical antibiotic available)
-TETRA-STEM – a tetracycline hydrochloride ointment. An award-winning antibiotic/wound healing product that kills all knows bacteria, including "flesh-eating" bacteria. Tertra-stem also can be used to treat wounds, ulcers
-topical anti-viral product (Viralcur) for genital herpes anti-fungal products for onychomycocis (OnyPro)
-hair loss prevention product (HairGain)
-ACNECLIR/ACNEEN – a salicylic acid based lotion that treats acne
-ECODERM – a colloidal oatmeal lotion for Eczema
-ACNECYCLINE – a tetracycline hydrochloride ointment that treats acne
-DERMONEEN – a salicylic acid lotion used to treat Psoriasis
-IVYMED – a zinc acetate based liquid that treats Poison Ivy rashes
- STAPHWASH PLUS – a zinc acetate based liquid. This is a non-antibiotic skin cleanser that kills MRSA
-TETRA-ABC – a tetracycline hydrochloride based ointment. This is an oil based topical antibiotic that kills all known bacterial infections. A water based version of this product is also available.
-STINGMED – a zinc acetate based liquid that treats most insect and spider bites
-ADVANCED JELLYFISH STING KIT – a zinc acetate powder, for suspension, that treats Jellyfish stings
-VENOMX – a zinc acetate based liquid used topically to treat snake bites.
-Product for treatment of Migraines presently; with a future of possibly ( inflammation of fibromyalgia, Cohn’s disease, nicotine addiction, schizophrenia, and pain management for Multiple Sclerosis and cancer. utilizing (CBD's) Calanoids and (THC) Tetrahydrocannabinol
biotechs trade at 30x earnings or 5x gross sales or 15x net sales or on air if they are a r and d company, with VDRM we have sales coming this year here is the analysis broken down below
ie...from the 500,000 bottles alone will yield $62.5M gross sales
$62.5m in gross sales X 5x gross sales = 325m market cap = $1.00 - $1.50 target
OR
62.5m in gross sales @ a 50% margin = $31m in net sales X 15x net sales = 450m market cap = $2.00 + target
OR
62.5m in gross sales with a $31m in net sales which divided by outstanding stock = 0.15 cents earnings X 30x earnings (pe - price to earnings) = $4.50 + target
Lead Product TetraStem
World’s strongest broad spectrum tetracycline-based topical antibiotic with proven results. Used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries.
Very low water content and optimum (low) viscosity. Uses both a chemical AND physical kill mechanism which is advantageous over traditional antibiotics which use only a chemical kill mechanism and has a better resistance profile.
Potential Markets
ViaDerma is developing products in many fields of use, including:
Topical antibiotics- $6 billion/year
Toenail antifungal drugs- $3 billion/year
Diabetic amputations- $3 billion/year
Global acne- $3.02 billion/year
Psoriasis- $7.3 billion/year
Eczema- $2.5 billion/year
Other potential markets include burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. Innovative, patent pending dual carrier transdermal technology which can transformoral medication into topical products. Ability to enable active ingredients with a rapid transport direct to the site of action.
Ability to be used in any field including Sports Nutrition Supplements, Cosmetics, First Aid Products, Wound Care, and Skin Diseases like Acne, Eczema, and Psoriasis. Dual carrier liquid which can possess life enhancing technology with up to four year shelf-life. Facilitates transfer of chemicals through the stratum corneum with
ICNB
Finally!! FDA Number for Premature Ejaculation Drug IS IN! LOS ANGELES, CA--(Marketwired - June 27, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has received its National Drug Code (NDC) 69006-010-00 from the Food and Drug Administration (FDA) for its new over the counter or OTC medication, Prolayed, a male genital desensitizer to delay onset of ejaculation.
The company's FDA Registered Prolayed combines Lidocaine as the active ingredient with ViaDerma's proprietary transdermal delivery system. The new "OTC Drug" is now ready for sale. The Company's recent testing has proved to be successful. The market for Premature Ejaculation (PE) is estimated to be $1.3 billion in 2017. The Company's topical solution does not have to be ingested and processed through the body's internal organs. The Company believes there is a vast market for this type of non-orally ingested new product and should generate significant Company revenues in the near future.
This is another product in the "Go to Market Strategies" pipeline. The Company already has located a suitable manufacturer and seeks distributors. The Company is continuing the completion of the labeling, quality control, marketing, and distribution now for several new products.
Premature ejaculation sprays became available in the UK in last year in November, but men wishing to use it would have to visit their Doctor, who would then order the spray from a pharmaceutical company. Now, men can purchase the spray themselves directly from an online pharmacy. In other reported testing, the product works on 9 out of 10 men and can have them last twice as long during sexual intercourse. Research reports have found the premature ejaculation treatment market has been estimated to be approximately $1.3 Billion dollars for 2017, up from about $684 million dollars in 2010 based on the U.S. and European approval of several new products. Trends, Technologies & Opportunities Report for 2016-2020 with key vendors being Pfizer, Emcure, Eli Lilly. In Technavio's report, Global Premature Ejaculation Treatment Market for the 4-year period states that the analysts forecast for the global PE treatment market to grow at a CAGR of 9.65% during that period.
Company Update
The production of the Company's topical antibiotic is still on track and the Company is finalizing purchase orders for the product which should be shipped to distributors within the next few weeks. Also, the Company has had new inquiries from distributors in South Korea, and a meeting is scheduled in the first week of July to finalize a sales agreement. The lawsuit filed against the Company has been answered and the Company's legal counsel Austin Legal Group, from San Diego, has filed a motion to dismiss the plaintiffs' claims in Federal Court.